Devyanshi Dixit։ Can Biomarkers Replace Trial-and-Error in Gynecologic Treatment?
Devyanshi Dixit, Program Manager at CLS Event and Publication and Conference Manager at the 12th Global Summit on Gynecology, Fertility and Women’s Health, shared on LinkedIn:
“Can biomarkers replace trial-and-error in gynecologic treatment?
What if doctors could know which treatment is more likely to work before a patient spends months trying different options?
That is one of the promises of biomarker-driven medicine.
A biomarker can be a measurable feature – such as a gene, protein, hormone, molecular signature, or imaging characteristic – that provides information about a biological process or disease.
Why does this matter in women’s health?
Two patients can have the same diagnosis but respond very differently to the same treatment.
- One may improve quickly.
- Another may experience side effects.
- A third may see little benefit.
Biomarkers could eventually help identify who is more likely to respond, who may be at greater risk of complications, or which disease pathway is active.
Where could this change care?
Endometriosis
Researchers are investigating molecular and inflammatory markers that could improve diagnosis and help classify disease.
Gynecologic cancers
Tumor biomarkers already play an important role in identifying molecular characteristics that can guide certain treatment decisions.
Infertility and reproductive medicine
Researchers are studying biomarkers related to ovarian reserve, embryo development, implantation, and reproductive outcomes.
Menopause and reproductive aging
Hormonal and molecular markers may help researchers better understand biological transitions and individual differences.
But there’s a big catch.
Many proposed biomarkers are still in the research stage.
So the future may not be:
Biomarker – perfect treatment
It may be:
Biomarker + clinical history + imaging + patient preferences – more informed decisions
The goal isn’t to remove the human judgment from medicine.
It’s to give clinicians better information before making a decision.
And that could gradually move gynecologic care from ‘What usually works?’ toward:
‘What is most appropriate for this patient?’
GFWH 2026 brings together researchers and clinicians exploring the future of precision medicine, diagnostics, reproductive health, and gynecologic innovation.
- November 23–24, 2026
- Bangkok, Thailand․”
Other articles featuring Devyanshi Dixit on Fertility News.
-
Sep 25, 2026, 17:57Devyanshi Dixit: Next-Gen Women’s Health at GFWH 2026
-
Sep 25, 2026, 17:53Szabó Gábor: Ultrasound vs MRI for Preoperative Detection of Endometriosis
-
Sep 25, 2026, 17:45Robert Gilchrist: Is There Anything More Important in IVF Than Eggs?
-
Sep 25, 2026, 17:41Justin Houman: How I Run a Men’s Health Practice Inside an Academic Medical Center
-
Sep 25, 2026, 17:39Kristen Williams: The Hills I Will Die on as a Women’s Healthcare Founder
-
Sep 25, 2026, 17:36Thankful to Everyone Who Attended the Current Practice in Therapeutic Sperm Preparation Day – ARCS
-
Sep 25, 2026, 17:27Akash Verma: Sperm Cryopreservation with FertiPro SpermFreeze
-
Sep 25, 2026, 17:21Rafael Trinchant: Thrilled to Share Our Article on Semen, Stigma, and Spectacle
-
Sep 25, 2026, 17:14Eric Lameignere: Are We Measuring the Right Sperm DNA Fragmentation?